Bilateral renal agenesis is a rare congenital anomaly associated with poor prognosis.
The aims of this article are to review and summarize evidence on prenatal diagnosis and outcomes of bilateral renal agenesis.
A search was undertaken using PubMed and ClinicalTrials.gov databases from January 1, 1998, to September 1, 2018. Search terms include “prenatal diagnosis” OR “outcomes” AND “bilateral renal agenesis.” Search was limited to English language.
Fetal ultrasonography is the primary imaging modality for prenatal diagnosis of fetal urogenital tract abnormalities. However, ultrasonography is limited by several factors; it is operator dependent and associated with small field of view, has limited soft-tissue acoustic contrast, and is also influenced by patient habitus and fetal position. Color Doppler ultrasonography can be used as an adjunct to exclude bilateral renal agenesis by visualizing renal arteries. In the literature, prenatal magnetic resonance imaging has been reported to be equal to or superior to prenatal ultrasonography. Bilateral renal agenesis with oligohydramnios/anhydramnios is associated with a poor prognosis; perinatal death occurs secondary to pulmonary hypoplasia in the majority of cases.
Ultrasonography in combination with color Doppler ultrasonography permits the fetal urinary tract to be assessed in the first and early second trimester of gestation. The magnetic resonance imaging can be used as a complementary adjunctive modality in equivocal or inconclusive ultrasonographic findings.
Obstetricians and gynecologists, family physicians.
After completing this activity, the learner should be able to describe the natural history of fetuses with bilateral renal agenesis; explain to patients the accuracy and limitations of the prenatal diagnosis of the anomaly; and counsel patients regarding the perinatal outcome and prognosis of fetuses with this condition.
*Medical Student, Medical University of Graz, Graz, Austria;
†Research Trainee, and
‡Resident in Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN;
§Associate Professor and Director of Fetal Therapy, Division of Maternal-Fetal Medicine and Obstetrics, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA;
∥Assistant Professor and Director of Johns Hopkins Children's Center Fetal Program, Division of Pediatric Surgery, The Johns Hopkins Hospital, Baltimore, MD; and
¶Professor of Obstetrics & Gynecology, Pediatrics and Physiology & Biomedical Engineering, Chair of the Division of Maternal-Fetal Medicine, and Director of Mayo Clinic Fetal Section, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN
All authors, faculty, and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations relevant to this educational activity.
The publication is approved by all authors and the responsible authorities of our hospital.
Correspondence requests to: Rodrigo Ruano, MD, PhD, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905. E-mail: email@example.com; firstname.lastname@example.org.